Y-mAbs Therapeutics, Inc. (YMAB) Class Action Notice:

SAN DIEGO, March 08, 2023 (GLOBE NEWSWIRE) --

The Class: Robbins LLP reminds investors that a shareholder filed a class action on behalf of all investors who purchased shares of Y-mAbs Therapeutics, Inc. (NASDAQ: YMAB) common stock between October 6, 2020 and October 28, 2022, for violations of the Securities Exchange Act of 1934. Y-mAbs is a clinical-stage biopharmaceutical company focused on developing antibody therapeutics and medicines for the treatment of cancer patients of all ages. The Company's lead product candidate is Omburtamab. According to Y-mAbs, '131I-omburtamab, which is omburtamab radiolabeled with Iodine-131, is currently being studied in several clinical trials including pivotal stage development Study 101 and Study 03-133 for the treatment of pediatric patients who have CNS/LM from NB.”

What Now: Similarly situated shareholders may be eligible to participate in the class action against Y-mAbs. Shareholders who want to act as lead plaintiff for the class must file their papers by March 20, 2023. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. You do not have to participate in the case to be eligible for a recovery. For more information, click here.

All representation is on a contingency fee basis. Shareholders pay no fees or expenses.

What is this Case аbout: Y-mAbs Therapeutics, Inc. (YMAB) Misrepresented the Viability and Efficacy of its Lead Drug Candidate

According to the complaint, Y-mAbs sought FDA approval of omburtamab through a Biologics License Application first in 2020 and again in 2022, based on a comparison between Study 03-133 performed at Memorial Sloan Kettering Cancer Center (“MSKCC”) and an external cohort comprising data from the Central German Childhood Cancer Registry, or CGCCR, database.

The FDA declined marketing approval of omburtamab in a Refusal to File (RTF) letter dated October 2, 2020, informing Y-mAbs that additional data, including evidence of durable response were necessary to provide the level of evidence needed to support an approval.

Y-mAbs disclosed the existence of the RTF letter in a press release dated October 5, 2020, and in an investor conference call the morning of October 6, 2020, but misrepresented the FDA’s willingness to approve omburtamab for marketing based on the existing clinical trials. In fact, during the class period, Y-mAbs misrepresented to investors that, pursuant to a series of meetings and other communications between Y-mAbs and the FDA, progress was being made that would align with the FDA’s requirement to demonstrate substantial evidence of effectiveness, sufficient for approval of omburtamab, through adequate and well-controlled studies.

To the contrary, the FDA had repeatedly advised the defendants that the FDA was unlikely to grant approval for the marketing of omburtamab based on a comparison between Study 03-133 and CGCCR because of substantial differences in the patient populations, and the absence of tumor response data, and that Study 101 was neither sufficiently advanced nor indicative of efficacy to justify approval. The truth was first disclosed to investors on October 26, 2022, when the FDA published its Briefing Document for an October 28, 2022 Advisory Committee Meeting, and again on October 28, 2022, when the Committee voted 16-0 against recommending approval of omburtamab. On this news, Y-mAbs common shares fell $11.56 per share, to close at $3.61 per share on October 31, 2022.

Contact us to learn more:

Aaron Dumas
(800) 350-6003
adumas@robbinsllp.com
Shareholder Information Form

About Robbins LLP: A recognized leader in shareholder rights litigation, the attorneys and staff of Robbins LLP have been dedicated to helping shareholders recover losses, improve corporate governance structures, and hold company executives accountable for their wrongdoing since 2002. To be notified if a class action against Y-mAbs Therapeutic, Inc. settles or to receive free alerts when corporate executives engage in wrongdoing, sign up for Stock Watch today.

Attorney Advertising. Past results do not guarantee a similar outcome.

Contact:
Aaron Dumas
Robbins LLP
5060 Shoreham Pl., Ste. 300
San Diego, CA 92122
adumas@robbinsllp.com
(800) 350-6003
www.robbinsllp.com

https://www.facebook.com/RobbinsLLP/
https://www.linkedin.com/company/robbins-llp/



Y-mAbs Therapeutics, Inc. (YMAB) Class Action Notice:

TIN LIÊN QUAN

HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Encourages Y-mAbs

SAN FRANCISCO, March 11, 2023 (GLOBE NEWSWIRE) -- Hagens Berman urges Y-mAbs Therapeutics, Inc. (NASDAQ: YMAB) investors who suffered significant losses...

Caribou Biosciences, Inc. (CRBU) Shareholder Alert: Robbins

SAN DIEGO, Feb. 17, 2023 (GLOBE NEWSWIRE) -- The Class: Robbins LLP reminds investors that a shareholder filed a class action on behalf of persons or...

Vertex Energy, Inc. (VTNR) Shareholder Notice: Robbins LLP

SAN DIEGO, March 09, 2023 (GLOBE NEWSWIRE) -- The Class: Robbins LLP reminds investors that a shareholder filed a class action on behalf of all persons...

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders

NEW YORK, Feb. 14, 2023 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against certain officers and directors of...

Notice of Filing Securities Class Action Against Global

NEW YORK, Feb. 09, 2023 (GLOBE NEWSWIRE) -- Lowey Dannenberg P.C. has filed a federal securities class action in the United States District Court...

Beam Therapeutics to Participate in the 43rd Annual Cowen

CAMBRIDGE, Mass., March 01, 2023 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic...

Lyra Therapeutics Announces Appointment of John Bishop,

WATERTOWN, Mass., Feb. 27, 2023 (GLOBE NEWSWIRE) -- Lyra Therapeutics, Inc. (Nasdaq: LYRA) (the Company or Lyra), a clinical-stage biotechnology company...

THỦ THUẬT HAY

Những ứng dụng và trò chơi nổi bật mới phát hành trên App Store

Hiện tại, trên cửa hàng ứng dụng App Store đã xuất hiện không ít ứng dụng mới dành cho iPhone và iPad. Tất nhiên không phải cái nào mới cũng hay và hữu ích. Để giúp bạn dễ dàng hơn trong việc tìm kiếm thêm ứng dụng cho

Thử ngay ứng dụng tạo ảo giác quang học miễn phí trên iPhone X

Trong tuần vừa rồi, anh đã đăng tải một trong những tính năng điển hình của Apple ARKit (Bộ AR của Apple) đó là có thể tạo nên ảo ảnh thị giác, nguyên lý dựa trên sự theo dõi chuyển động của khuôn mặt của iPhone X,

iPhone bị đơ và những cách khắc phục lỗi iPhone bị đơ

iPhone nổi tiếng với độ ổn định, mượt mà, tuy vậy sau một vài năm sử dụng hiện tượng iPhone bị đơ xảy ra cũng không phải chuyện hiếm.

20 plugin Photoshop miễn phí và hữu ích nhất cho các chuyên gia thiết kế

Những plugin hữu ích giúp bạn tăng năng suất làm việc và tiết kiệm thời gian khi sử dụng Photoshop.

Công cụ hỗ trợ tải ảnh từ Flickr cực kỳ đơn giản và thuận tiện

Công cụ mà mình muốn chia sẻ với các bạn chính là LMT Flickr Downloader của bạn Lê Minh Thành (tác giả DownloadZing, tool tải nhạc và video chất lượng cao miễn phí từ Zing Mp3, Zing TV, Nhaccuatui...).

ĐÁNH GIÁ NHANH

Đánh giá tủ lạnh Panasonic NR-BV289QSV2 Inverter 255 lít

Điểm nổi bật nhất là thiết kế khá nhỏ gọn với ngăn đá dưới tiện lợi giúp người dùng không phải khom lưng quỳ gối khi lấy thức phẩm thường xuyên ở ngăn mát. Với chiều cao chỉ hơn 150 cm một chút nên tầm với và tầm nhìn

iPhone X và Galaxy Note8: Siêu phẩm nào chụp camera tele đỉnh hơn?

Galaxy Note 8 và iPhone X đang là những siêu phẩm hàng đầu về camera phone hiện nay

Baic Q7: Ngoài giá bán, còn gì khác để thuyết phục khách hàng Việt Nam

Với mức giá niêm yết 658 triệu (tặng 100% phí trước bạ), BAIC Q7 là một lựa chọn tương đối hấp dẫn trong phân khúc CUV 5 chỗ. Tuy nhiên, ngoài giá bán thì chiếc xe này có gì khác để thuyết phục khách hàng Việt Nam, vốn